Call Today: 800-889-3898
Submit your Raptiva claim details for a free, no obligation case review
Get Started:
Several Raptiva-linked infections have been reported to the Food and Drug Administration (FDA) and its European counterpart, the European Medicines Agency (EMEA), and have been documented in clinical trials conducted by the manufacturer of Raptiva (efalizumab), Genentech. These infections include:
Death from PML, perhaps the most serious of the Raptiva infections, was confirmed in three Raptiva-treated patients in the U.S. and was published in an FDA alert issued Feb. 19, 2009. Based on the risk of Raptiva infections such as PML, the EMEA took the Raptiva medication off the market in Europe in early 2009. PML is an otherwise very rare nervous system/brain infection caused by a virus, and it's usually fatal. Contracting PML from a psoriasis medication is an unexpected and disastrous outcome.
The Prescribing Information provided by Genentech goes into great detail about Raptiva medication risks and the types of infections and other problems observed in Raptiva patients in controlled trials:
Meningitis, another very dangerous potential Raptiva side effect, is caused by inflammation of meninges —the protective membranes that cover the brain and spinal cord. The risk of contracting meningitis while being treated with Raptiva is described in the medication's Prescribing Information.
The most common symptoms of meningitis include:
A very serious illness, meningitis can have long-term consequences — hydrocephalus, cognitive deficits, epilepsy and deafness. Meningitis can be treated with antibiotics.
If you have taken Raptiva for psoriasis and you experienced any of the above-listed symptoms, see your doctor or a healthcare professional at an emergency room as soon as possible. You may have meningitis or another life-threatening infection.
The FDA has sent out several warning letters to healthcare professionals regarding the risk of infection presented by Raptiva. It is entirely possible that Raptiva will be pulled from the market in the U.S.
Individuals who have been harmed by Raptiva — whether from PML, meningitis, or another infection — have the right to pursue a legal remedy for losses they've incurred such as medical bills, disability and loss of income. Contact us to schedule a free consultation with an experienced Raptiva attorney in your area today.
The U.S. Food and Drug Administration (FDA) announced a voluntary Raptiva recall, April 8, 2009. The Psoriasis drug’s manufacturer, Genentech, announced the voluntary Raptiva recall and has begun phasing the drug off the U.S. market. R...
Copyright © 2001 - 2009 Online Lawyer Source | Legal Marketing Site Designed by eJustice